Mann, Johannes F.E.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 7,629

Dapagliflozin in Patients with Chronic Kidney Disease

Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 5,618

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthDialysis and Renal Disease Management

Cited by 2,614

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention

Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., Mann, J. F., Matsushita, K., & Wen, C. P. (2013) · The Lancet

Chronic Kidney Disease and DiabetesDialysis and Renal Disease Management

Cited by 2,213

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.

Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., et al. (2024) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 2,099

KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International

Blood Pressure and Hypertension StudiesChronic Kidney Disease and Diabetes

Cited by 1,452

Chronic Kidney Disease: Effects on the Cardiovascular System

Schiffrin, E. L., Lipman, M. L., & Mann, J. F. E. (2007) · Circulation

Chronic Kidney Disease and DiabetesDialysis and Renal Disease Management

Cited by 1,448

Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial

Mann, J. F. E., Gerstein, H. C., Pogue, J., Bosch, J., Yusuf, S., & for the HOPE Investigators (2001) · Annals of Internal Medicine

Chronic Kidney Disease and DiabetesBlood Pressure and Hypertension Studies

Cited by 1,372

Liraglutide and renal outcomes in type 2 diabetes

Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,253

Intensive supportive care plus immunosuppression in IgA nephropathy

Rauen, T., Eitner, F., Fitzner, C., Sommerer, C., Zeier, M., Otte, B., Panzer, U., Peters, H., Benck, U., Mertens, P. R., et al. (2015) · New England Journal of Medicine

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 726

Urinary sodium and potassium excretion and risk of cardiovascular events

O'Donnell, M. J., Yusuf, S., Mente, A., Gao, P., Mann, J. F., Teo, K., McQueen, M., Sleight, P., Sharma, A. M., Dans, A., et al. (2011) · JAMA

Sodium Intake and HealthBlood Pressure and Hypertension Studies

Cited by 564

Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Clase, C. M., Carrero, J.-J., Ellison, D. H., Grams, M. E., Hemmelgarn, B. R., Jardine, M. J., Kovesdy, C. P., Kline, G. A., Lindner, G., Obrador, G. T., et al. (2020) · Kidney International

Potassium and Related DisordersParathyroid Disorders and Treatments

Cited by 498

Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies

Mente, A., O'Donnell, M., Rangarajan, S., Dagenais, G., Lear, S., McQueen, M., Diaz, R., Avezum, A., Lopez-Jaramillo, P., Lanas, F., et al. (2016) · The Lancet

Sodium Intake and HealthBlood Pressure and Hypertension Studies

Cited by 483

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

McGuire, D. K., Marx, N., Mulvagh, S. L., Deanfield, J. E., Inzucchi, S. E., Pop-Busui, R., Mann, J. F. E., Emerson, S. S., Poulter, N. R., Engelmann, M. D. M., et al. (2025) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 416

Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

Badve, S. V., Bilal, A., Lee, M. M. Y., Sattar, N., Gerstein, H. C., Ruff, C. T., McMurray, J. J. V., Rossing, P., Bakris, G., Mahaffey, K. W., et al. (2025) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 359

Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes

Agarwal, R., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Rosenstock, J., Rossing, P., Vaduganathan, M., Brinker, M., et al. (2025) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 319

Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials

Böhm, M., Schumacher, H., Teo, K. K., Lonn, E. M., Mahfoud, F., Mann, J. F. E., Mancia, G., Redon, J., Schmieder, R. E., Sliwa, K., et al. (2017) · The Lancet

Blood Pressure and Hypertension StudiesRenin-Angiotensin System Studies

Cited by 315

The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis

Gerstein, H. C., Pogue, J., Mann, J. F. E., Lonn, E., Dagenais, G. R., McQueen, M., Yusuf, S., & HOPE investigators (2005) · Diabetologia

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 262

Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER

Shaman, A. M., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Mann, J. F. E., Nauck, M. A., Rasmussen, S., Rossing, P., et al. (2022) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 255

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

Rossing, P., Baeres, F. M. M., Bakris, G., Bosch-Traberg, H., Gislum, M., Gough, S. C. L., Idorn, T., Lawson, J., Mahaffey, K. W., Mann, J. F. E., et al. (2023) · Nephrology Dialysis Transplantation

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 242

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial

Colhoun, H. M., Lingvay, I., Brown, P. M., Deanfield, J., Brown-Frandsen, K., Kahn, S. E., Plutzky, J., Node, K., Parkhomenko, A., Rydén, L., et al. (2024) · Nature Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 238

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

Mann, J. F. E., Rossing, P., Bakris, G., Belmar, N., Bosch-Traberg, H., Busch, R., Charytan, D. M., Hadjadj, S., Gillard, P., Górriz, J. L., et al. (2024) · Nature Medicine

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 200

Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial

Buse, J. B., Bain, S. C., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Pratley, R. E., Linder, M., Monk Fries, T., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 175

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials

Mann, J. F. E., Hansen, T., Idorn, T., Leiter, L. A., Marso, S. P., Rossing, P., Seufert, J., Tadayon, S., & Vilsbøll, T. (2020) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 157